PTEN status in advanced colorectal cancer treated with cetuximab.
Br J Cancer
; 102(1): 162-4, 2010 Jan 05.
Article
em En
| MEDLINE
| ID: mdl-19953097
ABSTRACT
BACKGROUND:
Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal cancer (CRC) may represent one of the resistance mechanisms to cetuximab by interfering with the epidermal growth factor receptor signal transduction pathway.METHODS:
PTEN expression tested by indirect immunofluorescence was evaluated both on primary (n=43) and on metastatic (n=24) sites in CRC patients treated with cetuximab.RESULTS:
The loss of PTEN expression tested on metastatic sites was negatively associated with response (100% progressive disease (PD) in PTEN-negative cases vs 30% PD in PTEN-positive cases; P<0.05), PFS (0.8 vs 8.2 months; P<0.001) and OS (2.9 vs 14.2 months; P<0.001).CONCLUSION:
A potential role of PTEN in the anti-tumour activity of cetuximab could be hypothesised.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Colorretais
/
Adenocarcinoma
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Inibidores de Proteínas Quinases
/
PTEN Fosfo-Hidrolase
/
Receptores ErbB
/
Anticorpos Monoclonais
/
Proteínas de Neoplasias
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Br J Cancer
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
Itália